医药行业周报（2024年第47周）

Investment Rating - The report maintains an "Outperform the Market" rating for the pharmaceutical industry [4]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 3.9% during the week of November 11-15, 2024, ranking 18th among 31 sectors in the Shenwan classification [12][14]. - The overall scale of Beijing's pharmaceutical and health industry reached 976.1 billion RMB in 2023, laying a solid foundation for achieving a trillion-level leap [20]. - A significant strategic cooperation agreement worth 3.3 billion USD was signed between Merck Sharp & Dohme (MSD) and Chinese company Lixin Pharmaceutical Technology [25]. Summary by Sections 1. Pharmaceutical Industry Overview - The pharmaceutical sector's trading volume for the week was 624.336 billion RMB, with the chemical pharmaceutical industry having the highest trading volume at 180.94 billion RMB [12][18]. - The sector's performance was weaker than major market indices, with the Shanghai Composite Index down 3.5% and the Shenzhen Component Index down 3.7% [12]. 2. Industry News and Important Announcements 2.1 Industry News - The Beijing pharmaceutical health industry is attracting foreign investment, with several multinational companies establishing R&D centers in the city [20]. - The National Healthcare Security Administration announced improvements to the prepayment management system for medical insurance funds to alleviate financial pressure on medical institutions [23]. - A second batch of medical service price governance was announced, targeting specific tumor marker tests for price adjustments [24]. 2.2 Important Announcements - Huadong Medicine received approval for the first domestically approved biosimilar injection of Ustekinumab [26]. - Beijing Jiukang Biotechnology obtained a patent for a preparation method of a coupling agent, enhancing its competitive edge [29]. - Hai Zheng Pharmaceutical's two veterinary drugs have met the conditions for market sales [30]. - Chengda Pharmaceutical's Dapagliflozin raw material drug has passed the CDE approval [31]. - China Pharmaceutical's subsidiary has passed the consistency evaluation for a generic drug, which will enhance its market share [32].